PolyPeptide Group

PolyPeptide Group AG is a publicly traded Contract Development and Manufacturing Organization (CDMO) headquartered in Baar, Switzerland, trading on the SIX Swiss Exchange under the ticker PPGN — a corporate structure and scale that sets it apart from the direct-to-researcher retail vendors that make up most of the Peptides.SO supplier directory. The company positions itself as a market leader in peptide active pharmaceutical ingredient (API) manufacturing, developing and producing both proprietary and generic peptide APIs for pharmaceutical and biotechnology clients rather than selling finished research vials to individual laboratories.

PolyPeptide's service architecture spans the full peptide development lifecycle: pre-GMP development, GMP-compliant commercial-scale production, quality assurance and quality control, and regulatory support, alongside dedicated Custom R&D services covering both research-grade peptide synthesis and radiolabeled peptide production for tracer and imaging applications. The company also maintains a generic peptide API manufacturing line and has publicly emphasized a "green peptide chemistry" initiative aimed at more sustainable production processes — a technology differentiator among peptide CDMOs.

In 2026, PolyPeptide became the subject of a formal tender offer from Samsung Biologics to acquire the company at CHF 44.31 per share, a notable corporate development following a period of market speculation about the company's ownership — a piece of context relevant to researchers or institutional partners evaluating the company's long-term manufacturing continuity. As a GMP/non-GMP dual-capability manufacturer serving pharmaceutical clients rather than a direct-to-consumer research chemical vendor, PolyPeptide's profile reflects institutional-scale peptide API production rather than catalog retail sales.